Sirion and Denali announce collaboration to develop gene therapies for neurodegenerative diseases


On 9 January, the global leader in viral vector-based gene delivery technologies SIRION Biotech GmbH has announced its collaboration with the biopharmaceutical company Denali Therapeutics which develops product candidates for neurodegenerative diseases. According to the licence and agreement, both companies will combine their platforms to create new adeno-associated virus vectors capable to allow therapeutics to cross the blood-brain barrier - a semipermeable membrane that protects the brain - with high efficiency. These gene therapies would target neurodegenerative diseases including Alzheimer’s and Parkinson’s disease.